Any prior cumulative doxorubicin dose must be ?  mg/m; prior cumulative epirubicin dose must be ?  mg/m.
History of exposure to cumulative doxorubicin dose ?  mg/meter squared. If another anthracycline or more than one anthracycline has been used, then the cumulative dose must not exceed the equivalent of  mg/meter squared of doxorubicin
Greater than  weeks from doxorubicin at the time of consent, with radiation to be initiated no less than  weeks from doxorubicin
Cumulative dose of doxorubicin or equivalent of >  mg/m^ during prior adjuvant therapy
Received previous systemic chemotherapy with a cumulative dose of >  mg/m^ of epirubicin or >  mg/m^ of doxorubicin
If liposomal doxorubicin hydrochloride (DOXIL) is selected as the investigators choice chemotherapy:\r\n* Lifetime exposure to doxorubicin =<  mg/m^ (or equivalent biologic dose if prior exposure to a different anthracycline)
Cumulative anthracycline exposure greater than mg/m^ doxorubicin equivalents prior to enrollment
Cumulative doxorubicin dose >=  mg/m^ (>  mg/m^ for malignant soft tissue and bone tumor patients) or cumulative epirubicin dose >=  mg/m^
Cumulative anthracyclines must not exceed  mg/m^ doxorubicin equivalents following completion of treatment on protocol; therefore for patients receiving one course on protocol cumulative anthracyclines must be less than or equal to  mg/m^ doxorubicin equivalents at the time of enrollment
Prior anthracycline cumulative dose below  mg/m or the daunorubicin equivalent which is the recommended non-cardiotoxic level.
Patients with a prior cumulative cisplatin dose >  mg/m^ (pertains to Arm A only)
Patients have received a cumulative dose of doxorubicin of greater than  mg/m^ or epirubicin of greater than  mg/m^
Patients who have received a cumulative doxorubicin equivalent of >  mg/m^ total lifetime dose
Prior therapy resulting in cumulative epirubicin dose >=  mg/m^ or cumulative doxorubicin dose >= mg/m^ or equivalent dose of another anthracycline
Patients who have received a cumulative dose of doxorubicin of greater than  mg/m^ or epirubicin of greater than  mg/m^
Planning to initiate treatment with doxorubicin (starting dose of  mg/m^) and olaratumab (starting dose of  mg/kg) as routine care
Cumulative lifetime anthracycline dose of =< mg/m^
Prior cumulative dose of doxorubicin of greater than  mg/m^ or epirubicin of greater than  mg/m^
Prior anthracycline therapy does not exceed  mg/m^ total cumulative dose
Previous treatment with complete cumulative doses of daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones that is equivalent to a total dose of >  mg/m^ doxorubicin
If history of exposure to anthracyclines during perioperative treatment, the following cumulative doses of anthracyclines must be less than:\r\n* Epirubicin <  mg/m^\r\n* Doxorubicin or liposomal doxorubicin <  mg/m^\r\n* Mitoxantrone >  mg/m^ and idarubicin >  mg/m^\r\nIf more than one anthracycline has been used, then the cumulative dose must not exceed the equivalent of  mg/m^ of doxorubicin
Prior exposure to > mg/m of doxorubicin or liposomal doxorubicin.
History of exposure to cumulative doses of doxorubicin greater than  mg per square meter of body-surface area or its equivalent
Patients with treatment related myeloid neoplasms with cumulative anthracyclines greater than  mg/m^ doxorubicin equivalents
No more than a total cumulative dose of  mg/m^ of prior doxorubicin chemotherapy
Cumulative lifetime dose of anthracycline chemotherapeutic >  mg/m^
Patients who have received prior doxorubicin may not have had more than  mg/m^ total dose and must have a normal left ventricular ejection fraction (LVEF) (>= %); (this includes Doxil or other liposomally encapsulated doxorubicin preparations)
The participant received previous chemotherapy with a cumulative dose of > mg per meter squared (mg/m^) of epirubicin or > mg/m^ of doxorubicin.
Prior treatment with anthracyclines at cumulative doses of  mg/m or more for doxorubicin or  mg/m or more for epirubicin
Prior exposure to cumulative doses of doxorubicin > mg/m or epirubicin > mg/m
Prior treatment with doxorubicin or other anthracycline at cumulative doses greater than  mg/m (calculated using doxorubicin equivalent doses:  mg doxorubicin =  mg Doxil/Caelyx = . mg epirubicin = . mg mitoxantrone = . mg idarubicin)
Subject has received a cumulative anthracycline dose above  mg/m of doxorubicin (or cumulative maximum dose of another anthracycline).
History of exposure at any time to the following cumulative doses of anthracyclines:\r\n* Doxorubicin or liposomal doxorubicin >  mg/m^\r\n* Epirubicin >  mg/m^\r\n* Mitoxantrone > mg/m^\r\n* Another anthracycline, or more than one anthracycline used in a cumulative dose exceeding the equivalent of doxorubicin  mg/m^
Prior cumulative exposure to doxorubicin (including liposomal preparation) >  mg/m^
Patients with therapy-related AML or MDS should have not received prior cumulative anthracycline (daunorubicin equivalent) lifetime dose >  mg/m^
Patient had prior exposure to a cumulative dose of doxorubicin that exceeded  mg/m or its equivalent.
Received prior therapy resulting in a cumulative epirubicin dose >  mg/m^ or cumulative doxorubicin dose >  mg/m^; if another anthracycline or more than one anthracycline has been used, the cumulative dose must not exceed the equivalent of  mg/m^ doxorubicin
Previous treatment with complete cumulative doses of daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones that is equivalent to a total dose of  mg/m^ doxorubicin
Prior treatment with doxorubicin (doxorubicin hydrochloride) up to  mg/m^
History of exposure to the following cumulative doses of anthracyclines: Doxorubicin >  mg/m; Epirubicin or Liposomal Doxorubicin-Hydrochloride (Myocet) >  mg/m; For other anthracyclines, exposure equivalent to doxorubicin >  mg/m
Patients with prior cumulative anthracycline exposure of greater than  mg/m daunorubicin (or equivalent).
Maximum prior cumulative doxorubicin dose of =<  mg/m^ or equivalent
Cumulative anthracycline exposure greater than  mg/m^ doxorubicin isotoxic equivalents
Prior treatment with cumulative dose of doxorubicin or equivalent exceeding  mg/m
History of cumulative doxorubicin or liposomal doxorubicin dose >  mg/m^
Prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than  mg/m, or of epirubicin dose of greater than  mg/m, or the equivalent dose for other anthracyclines or derivatives (part  only).
No more than  prior lines of chemotherapy; prior therapy with doxorubicin is permitted but no more than lifetime cumulative dose of  mg/m^; at least  weeks since prior chemotherapy or radiotherapy, at least  weeks if the last regimen included bis-chloroethylnitrosourea (BCNU) or mitomycin C
Patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative
Prior anthracycline therapy with a cumulative dose of doxorubicin (or equivalent) >=  mg/m^
Any prior cumulative doxorubicin dose must be ?  mg/m; prior cumulative epirubicin dose must be ?  mg/m.
Prior exposure to greater than  mg/m doxorubicin or liposomal doxorubicin, greater than  mg/m mitoxantrone, greater than  mg/m idarubicin, or greater than  mg/m epirubicin
Doxorubicin or liposomal doxorubicin > mg/m.
Epirubicin > mg/m.
If another anthracycline or more than  anthracycline has been used, then the cumulative dose must not exceed the equivalent of  mg/m of doxorubicin.
Patients with prior cumulative anthracycline exposure of greater than  mg/m daunorubicin (or equivalent)
Prior exposure to > mg/m of doxorubicin or liposomal doxorubicin.
Time to treatment failure from doxorubicin containing regimen ?  months if previously treated with doxorubicin.
Previous anthracycline-based chemotherapy (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone and valrubicin), in any formulation.
Prior therapy with anthracyclines exceeding the following doses (subjects will be discontinued at  mg/m lifetime dose irrespective of the number of ThermoDox cycles received): Free (i.e., non-liposomal) or liposomal doxorubicin >  mg/m Free epirubicin >  mg/m.
Prior cumulative doxorubicin dose >  mg/m^
Patients with prior cumulative anthracycline exposure of greater than  mg/m daunorubicin (or equivalent)
Prior treatment with anthracyclines at cumulative doses of  mg/m or more for doxorubicin or  mg/m or more for epirubicin
Cohort : Soft tissue sarcoma of intermediate or high grade with evidence of disease progression by either CT or MRI scan, or clinical judgment on or after the last cancer therapy within  months prior to the start of study treatment. Relapsed or refractory (lack of response) to ? course of systemic therapy regimen(s), excluding adjuvant or neoadjuvant chemotherapy, and is incurable by either surgery or radiation. Patients who have previously received anthracyclines are eligible if cumulative exposure is < mg/m for doxorubicin and liposomal doxorubicin or < mg/m for EPI.
Prior exposure to > mg/m of doxorubicin or liposomal doxorubicin or ? mg/m of EPI.
Chemotherapy must be planned for at least  cycles of full-dose anthracycline or taxane based chemotherapy regimen\r\n* Defined as one of the following regimens: \r\n** Adriamycin  mg/m with cyclophosphamide  mg/m \r\n** Epirubicin - mg/m with cyclophosphamide  mg/m \r\n** Doxorubicin  mg/m with -fluroruacil  mg/m and cyclophosphamide  mg/m \r\n** Paclitaxel  mg-/m weekly (every three weeks constitute a cycle), or  mg/m every - weeks as a single agent \r\n** Docetaxel  mg/m as a single agent \r\n** Docetaxel  mg/m with cyclophosphamide  mg/m \r\n** Docetaxel  mg/m with carboplatin area under the curve (AUC) of  and traztuzumab at standard doses\r\n* Concurrent traztuzumab at standard doses is allowed\r\n* Concurrent pertuzumab at standard doses is allowed\r\n* Administration of chemotherapy on a dose dense schedule is allowed as clinically indicated
Lifetime cumulative anthracycline dose: >=  mg/m^ without the protection of dexrazoxane (Zinecard) therapy
If in Arm D (doxorubicin and cyclophosphamide), patients with prior cumulative doxorubicin dose of >=  mg/m^
Scheduled to receive chemotherapy with an Anthracycline (doxorubicin or epirubicin)
Scheduled to receive chemotherapy with an anthracycline (doxorubicin [doxorubicin hydrochloride] or epirubicin [epirubicin hydrochloride])
Prior exposure to more than  mg/m^ doxorubicin, more than  mg/m^ mitoxantrone, or more than  mg/m^ idarubicin, or elevated baseline cardiac troponin I
Prior exposure to anthracyclines at a cumulative dose of doxorubicin (or equivalent) >  mg/m